Literature DB >> 7902536

Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study.

D R Hoover1, A J Saah, H Bacellar, J Phair, R Detels, R Anderson, R A Kaslow.   

Abstract

BACKGROUND: Among patients infected with human immunodeficiency virus type 1 (HIV-1), early and widespread use of prophylactic regimens against Pneumocystis carinii is changing the pattern of illnesses related to the acquired immunodeficiency syndrome (AIDS).
METHODS: We conducted a subcohort analysis of 844 men with AIDS (87 percent of whom have since died) from a prospectively followed cohort of 2592 HIV-1-infected homosexual men.
RESULTS: A total of 138 men received prophylaxis before the diagnosis of AIDS, but 39 (28 percent) nevertheless had P. carinii pneumonia at some time. Only four illnesses occurred more frequently in men who received P. carinii prophylaxis before the onset of AIDS: Mycobacterium avium complex disease, which developed in 33.4 percent, as compared with 17.3 percent of the 706 men who did not receive early prophylaxis; wasting syndrome (18.4 percent vs. 6.4 percent); cytomegalovirus disease (44.9 percent vs. 24.8 percent); and esophageal candidiasis (21.3 percent vs. 12.8 percent). Collectively, these four diseases accounted for the initial AIDS-related illness in 42.7 percent of those who received prophylaxis before the onset of AIDS, as compared with 10.7 percent of those who did not. During the three six-month periods before the diagnosis of AIDS (0 to 6, > 6 to 12, and > 12 to 18 months), the geometric mean CD4+ cell counts were 48, 87, and 147 per cubic millimeter, respectively, in men who received prophylaxis against P. carinii, as compared with 118, 211, and 279 per cubic millimeter in those who did not.
CONCLUSIONS: M. avium complex disease, esophageal candidiasis, wasting syndrome, and cytomegalovirus disease are more common in HIV-infected patients who have received prophylaxis against P. carinii than in those who have not. Prophylaxis may delay the first AIDS illness for 6 to 12 months.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7902536     DOI: 10.1056/NEJM199312233292604

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  66 in total

1.  Anthropometric indices as predictors of survival in AIDS adults. Aquitaine Cohort, France, 1985-1997. Groupe d'Epidémiologie Clinique du Sida en Aquitaine (GECSA).

Authors:  R Thiébaut ; D Malvy; C Marimoutou; F Davis
Journal:  Eur J Epidemiol       Date:  2000       Impact factor: 8.082

2.  Clinical and economic aspects of prophylaxis and treatment of Pneumocystis carinii pneumonia.

Authors:  K A Freedberg
Journal:  Pharmacoeconomics       Date:  1995-02       Impact factor: 4.981

Review 3.  Susceptibility testing of Mycobacterium avium complex isolates.

Authors:  L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

Review 4.  Can we predict the prognosis of HIV infection? How to use the findings of a prospective study.

Authors:  N Low; M Egger
Journal:  Sex Transm Infect       Date:  1998-04       Impact factor: 3.519

5.  Efficacy of sulfamethoxypyridazine in a murine model of Pneumocystis carinii pneumonia.

Authors:  M S Bartlett; M M Shaw; J W Smith; S R Meshnick
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

Review 6.  Prevention of infection due to Pneumocystis carinii.

Authors:  J A Fishman
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

Review 7.  Epidemiological and clinical aspects of mycobacterial infections.

Authors:  M Opravil
Journal:  Infection       Date:  1997 Jan-Feb       Impact factor: 3.553

Review 8.  Ophthalmic complications of HIV/AIDS.

Authors:  F G Ah-Fat; M Batterbury
Journal:  Postgrad Med J       Date:  1996-12       Impact factor: 2.401

Review 9.  The effects of long term zidovudine therapy and Pneumocystis carinii prophylaxis on HIV disease. A review of the literature.

Authors:  D R Hoover
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

Review 10.  Cidofovir.

Authors:  A P Lea; H M Bryson
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.